Posted by Michael Wonder on 01 Oct 2025
Enhertu followed by THP supplemental biologics license application accepted in the US for patients with high risk HER2 positive early stage breast cancer prior to surgery
1 October 2025 - Based on results from DESTINY-Breast11, the first Phase 3 trial to demonstrate benefit of Daiichi Sankyo and AstraZeneca’s Enhertu in early stage breast cancer.
Daiichi Sankyo and AstraZeneca’s supplemental biologics license application for Enhertu (trastuzumab deruxtecan-nxki) followed by paclitaxel, trastuzumab and pertuzumab has been accepted for review in the US for the neo-adjuvant treatment of adult patients with HER2 positive (IHC 3+ or ISH+) stage 2 or stage 3 breast cancer.
